Key regions: France, India, United Kingdom, South Korea, Japan
The Moldovan healthcare sector has been undergoing significant changes in recent years, with the government investing in healthcare infrastructure and increasing access to healthcare services. As a result, the Multiple Sclerosis Drugs market in Moldova has been experiencing steady growth.
Customer preferences: Patients suffering from Multiple Sclerosis in Moldova prefer drugs that have been approved by the European Medicines Agency (EMA). They also prefer drugs that have a good safety profile and are effective in managing the symptoms of the disease. Patients tend to rely on their physicians to prescribe the most appropriate drugs for their condition.
Trends in the market: The Multiple Sclerosis Drugs market in Moldova has been growing at a steady pace due to the increasing prevalence of the disease in the country. The market has been witnessing the entry of new drugs that have been approved by the EMA. These drugs offer better efficacy and safety profiles compared to the older drugs. The market has also been witnessing an increase in the use of generic drugs due to their affordability.
Local special circumstances: Moldova is one of the poorest countries in Europe, and the healthcare sector is underfunded. The government has been investing in healthcare infrastructure, but there is still a long way to go. The lack of funding has resulted in a shortage of healthcare professionals, including neurologists. This has led to delays in the diagnosis and treatment of Multiple Sclerosis, which has a negative impact on the market.
Underlying macroeconomic factors: The Moldovan economy has been growing at a slow pace, and the country is heavily dependent on remittances from abroad. The healthcare sector is underfunded, and there is a shortage of healthcare professionals. The government has been investing in healthcare infrastructure, but there is still a long way to go. The lack of funding has resulted in a shortage of drugs and medical equipment, which has a negative impact on the market. The market is also affected by the political instability in the country, which has resulted in a lack of investment and a poor business environment.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
